A Phase II of Intraperitoneal Catumaxomab as a Consolidation Therapy in Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma in Second or Third Complete Clinical Disease Remission

Trial Profile

A Phase II of Intraperitoneal Catumaxomab as a Consolidation Therapy in Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma in Second or Third Complete Clinical Disease Remission

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2016

At a glance

  • Drugs Catumaxomab (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Feb 2015 Status changed from recruiting to completed, according to European Clinical Trials Database record.
    • 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 06 Jun 2011 Ongoing trial data presented at the 47th Annual Meeting of the American Society of Clinical Oncology. An interim analysis of the first 6 patients enrolled is planned.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top